Genkyotex's GKT137831 Found to Reverse Fibrosis and Improve Survival in a Model of Persistent Lung Fibrosis
by Jim Bakken
“Specifically, we were able to demonstrate that established fibrosis in lungs of aged mice is partially reversed by administration of GKT137831, a new NOX inhibitor from Genkyotex,” explained Victor J. Thannickal, MD, Professor of Medicine and Pathology, Director, Division of Pulmonary, Allergy, and Critical Care, University of Alabama at Birmingham.